Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The resurrection of coenzyme Q10: It’s all about the money

David L. Katz, MD
Meds
March 26, 2013
79 Shares
Share
Tweet
Share

A recent meta-analysis published in the American Journal of Clinical Nutrition suggests that coenzyme Q10 is of benefit in congestive heart failure. For those who like the idea that food and nutrients can be excellent medicine, this paper is interesting at the very least. But there is a case to be made that it is far more than that. There is a case to be made that it is, in a word, miraculous.

For resurrection, after all, is a miracle. And according to a paper published in the Annals of Internal Medicine in April of 2000, coenzyme Q10 for heart failure was a dead concept. The authors reported 13 years ago that “coenzyme Q10 has been studied in randomized, blinded, and controlled studies and … these studies have found no detectable benefit” and that “coenzyme Q10 should not be recommended for treatment of heart failure.”

The final nail had been driven into the CoQ10-for-heart-failure hypothesis 13 years ago — and yet now, it’s back. If that’s not a miracle — then what is going on?

First, a bit of relevant orientation. The condition in question here, congestive heart failure, occurs in particular in the aftermath of one or more heart attacks (myocardial infarctions) which cause portions of the heart muscle to die for want of oxygen. Those areas stop pumping, of course, and the whole heart does its job less well.

The pumping efficiency of the heart is routinely measured using ultrasound as the “left ventricular ejection fraction” (LVEF), which, as the name suggests, is the proportion of blood the left ventricle is able to pump out of itself when it contracts. Roughly 55 to 70 percent is considered normal. High values can occur when the heart is stiff and muscle-bound, and tend to mean the heart empties well, but fills poorly. Congestive heart failure is associated with low values.

And that, in principle is where coenzyme Q10 (also known as ubiquinone, because it is all but “ubiquitous” in plants, albeit at very low concentrations) comes in. A coenzyme supports the work of one or more enzymes, and CoQ10 supports enzymes in the mitochondria, the energy generators of our cells, that transfer electrons. Perhaps you recall ATP, the body’s principal form of stored energy, from high school biology. Well, CoQ10 helps us make it.

Since ATP represents stored energy muscle cells can use to contract, and inadequate contraction is the problem in congestive heart failure, it is plausible that coenzyme Q10 might help.

So why didn’t it in the April, 2000 study in the Annals? Well, of course it’s possible that it really doesn’t work. Not every good and plausible idea is right — that’s why we need good science and unbiased methods. We fall all too readily in love with our own hypotheses, and only robust, objective methods can save us from that tendency.

But there’s another good explanation. The study in question enrolled a total of 55 adults — of whom nine failed to finish. The study lasted a total of six months. So, in 46 adults already on what was optimal medication for congestive heart failure at the time, CoQ10 for six months did not produce a discernible improvement in the LVEF.

The problem with that was revealed almost exactly a year later. In May of 2001, results of the CAPRICORN trial were published in the Lancet. CAPRICORN demonstrated that the proprietary drug carvedilol, patented and marketed as Coreg by GlaxoSmithKline, was effective in reducing mortality from congestive heart failure. It did so by enrolling nearly 2,000 patients and following them for a span of years.

Had carvedilol been studied in 46 patients for six months, it’s quite clear that nothing of consequence would have been seen. Presumably, on that basis, the final nail might have been driven into the carvedilol-for-heart-failure hypothesis. But a huge trial, costing many millions of dollars, and funded by the company that stood to profit from its results — precluded that unhappy outcome.

What would the result have been if coenzyme Q10 had been studied in 2,000 people followed for years? Nobody knows. Since no one company can patent CoQ10, no entity is motivated to fund such a trial. Certainly the new meta-analysis, which pools data from multiple smaller studies, suggests the results of a larger trial of CoQ10 might be very different. I have been aware of this possibility all along, have recommended CoQ10 to some of my patients with heart failure, and been impressed with the apparent effects on more than one occasion.

My clinical practice since 2000 is an Integrative Medicine Center I direct. I have taken some heat over the years for my support of integrative medicine from self-appointed arbiters of science. But, in fact, I have no special interest in CAM or integrative medicine. I just have a special interest in helping my patients get better — and conventional medicine hasn’t always gotten the job done.

Neither, of course, does CAM — so the open-minded skeptic looks at both with the same cautious eye.

It is well established that much, even most, of what constitutes conventional medicine is just tradition and not truly evidence-based by today’s standards. My own work in evidence mapping, a technique colleagues and I invented that was subsequently adopted by the World Health Organization, reveals that the evidence base underlying practices in CAM is quite diverse. The simple summary of it all is that there is both baby and bathwater in CAM and conventional medicine alike, and it requires open-mindedness and unbiased methods to distinguish between them.

It also requires money, which brings us full circle.

Reports of nails in CAM’s coffin tend to be premature — because the many unpatentable modalities in the realm of CAM do not inspire huge and costly trials. We need such trials to know for sure what does and doesn’t work. In the absence of them, we have absence of evidence, not evidence of absence — and need to avoid a rush to judgment. Io believe at this point that CoQ10 is beneficial in heart failure — but don’t know for sure.

The story of CoQ10′s resurrection for heart failure across a span of more than a decade is in fact, not a tale of miracles. It’s all about money.

David L. Katz is the founding director of Yale University’s Prevention Research Center. 

Prev

Baby cured of HIV: What's the real story?

March 25, 2013 Kevin 2
…
Next

Our most scarce health resources are asked to carry the largest load

March 26, 2013 Kevin 9
…

Tagged as: Cardiology, Medications

Post navigation

< Previous Post
Baby cured of HIV: What's the real story?
Next Post >
Our most scarce health resources are asked to carry the largest load

More by David L. Katz, MD

  • There are only 3 ways to allocate health care resources

    David L. Katz, MD
  • Dr. Oz: I have met the enemy. It is us.

    David L. Katz, MD
  • a desk with keyboard and ipad with the kevinmd logo

    The dietary guidelines are for which Americans, exactly?

    David L. Katz, MD

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Tom Brady’s legacy and the importance of personal integrity in end-of-life choices

      Kevin Haselhorst, MD | Physician
    • The hidden truths of hospital life: What doctors wish you knew

      Emily Stanford, DO | Physician
    • 10 commandments of ethical affiliate marketing for physicians

      Aaron Morgenstein, MD & Amy Bissada, DO | Finance
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 5 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Journal Shows Its Commitment to Exploring AI in Medicine
  • Do Away With 'Lockout' Period in iPLEDGE, FDA Advisors Urge
  • Cluster Headache, Migraine Linked to Circadian System
  • Smaller Liver Transplant Candidates Wait Longer, Less Likely to Receive Organ
  • A 'Double Whammy' for Gastric Cancer Risk

Meeting Coverage

  • Oral Roflumilast Effective in the Treatment of Plaque Psoriasis
  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Less Abuse With Extended-Release Oxycodone, Poison Center Data Suggest
  • Novel Strategies Show Winning Potential in Ovarian Cancer
  • Most Popular

  • Past Week

    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Tom Brady’s legacy and the importance of personal integrity in end-of-life choices

      Kevin Haselhorst, MD | Physician
    • The hidden truths of hospital life: What doctors wish you knew

      Emily Stanford, DO | Physician
    • 10 commandments of ethical affiliate marketing for physicians

      Aaron Morgenstein, MD & Amy Bissada, DO | Finance
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The resurrection of coenzyme Q10: It’s all about the money
5 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...